Status
Conditions
Treatments
About
Our general objective, during this study, is to evaluate the feasibility and potential physiological benefits of using REBOA (resuscitative endovascular balloon occlusion of the aorta) CPR (cardiopulmonary resuscitation) for patients presenting with a cardiac arrest to a community hospital. This would represent the first step for doing a larger, randomized clinical trial on the use of REBOA in non-traumatic cardiac arrest.
Full description
Primary objective: Validate the feasibility of using REBOA in a community hospital setting during cardiac arrest as an adjunct to ACLS (advances cardiac life support) . This will be done by measuring time to REBOA placement and successful inflation. Furthermore, we will also document any REBOA related complications.
Secondary objectives: Evaluate the potential physiological benefits of REBOA for human subjects in NTCA (non traumatic cardiac arrest) that are not responding to standard ACLS.
Study Design and Methodology Trial design The trial is a single-center, single-arm, open (unblinded), feasibility, experimental study.
Study Duration The study is expected to begin in winter 2022 and last approximately 12 months. Population studied The population studied will be patients in non-traumatic cardiac arrest at Santa Cabrini Hospital, aged 18-75 years old.
Patients presenting with a witnessed cardiac arrest (out of hospital cardiac arrest (OHCA) or in hospital cardiac arrest (IHCA)) and in which ACLS was performed for at least 15 minutes or BLS for at least 30 minutes and for no more than 60 minutes will be evaluated for eligibility to participate in the study.
Number of patients 20
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Suspected reversible cause of cardiac arrest (except for trauma), with one of any of the following prognostic signs30
Body habitus accommodating automated Lund University Cardiac Arrest System (LUCAS)
Level of care includes CPR, or unable to obtain level of care (if possible, validate with relative)
More than 15 minutes of ACLS with no ROSC or more than 30 minutes of BLS with no ROSC
Exclusion criteria
Transfer accepted for ECPR
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Lawrence Leroux, MD; Philippe Rola, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal